

10/577382

1AP20 Res PCT PTO 27 APR 2006
Dkt. 68548-PCT-US/JPW/JW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Shi Du Yan, et al.
U.S. Serial No. : Not Yet Known (national stage of PCT
International Application No.
PCT/US2004/036173)
Filed : Herewith
For : METHODS FOR REDUCING SEIZURE-INDUCED
NEURONAL DAMAGE

1185 Avenue of the Americas
New York, New York 10036
April 27, 2006

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In order to ensure compliance with applicants' duty of disclosure under 37 C.F.R. §1.56 and §1.97(a)-(d), applicants request that the following documents be considered and made of record in the above-identified application which is listed on Form PTO-1449, attached hereto as **Exhibit A**:

1. International Search Report issued by the International Searching Authority (ISA/US) on April 7, 2005 in connection with International Application No. PCT/US2004/036173 (**Exhibit 1**);
2. Tsuji H, Iehara N, Masegi T, Imura M, Ohkawa J, Arai H, Ishii K, Kita T, and Doi T. (1998) Ribozyme Targeting of Receptor for Advanced Glycation End Products in Mouse Mesangial Cells. *Biochem. Biophys. Res. Commun.* 245: 583-588 (**Exhibit 2**);

3. Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahl P, Ziegler R, Müller M, and Nawroth PP. (1997) Advanced Glycation End Product (AGE)-Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE. *Circulation* 96: 2262-2271 (**Exhibit 3**);
4. Sajithlal G, Huttunen H, Rauvala H, and Münch G. (2002) Receptor for Advanced Glycation End Products Plays a More Important Role in Cellular Survival than in Neurite Outgrowth during Retinoic Acid-induced Differentiation of Neuroblastoma Cells. *J. Biol. Chem.* 277(9): 6888-6897 (**Exhibit 4**);
5. Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, and Schmidt AM. (1996) RAGE and amyloid- β peptide neurotoxicity in Alzheimer's disease. *Nature* 382: 685-691 (**Exhibit 5**);
6. U.S. Patent No. 6,506,559 B1 (FIRE et al.), published January 14, 2003 (**Exhibit 6**);
7. U.S. Patent Application Publication No. 2003/0013699 A1 (DAVIS et al.), published January 16, 2003 (**Exhibit 7**);
8. Jen K-Y and Gewirtz AM. (2000) Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Option and Current Strategies. *Stem Cells* 18: 307-319 (**Exhibit 8**);
9. Branch AD. (1998) A good antisense molecule is hard to find. *TIBS* 23: 45-50 (**Exhibit 9**);

10. Green DW, Roh H, Pippin J, and Drebin JA. (2000) Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease. *J. Am. Coll. Surg.* 191(1): 93-105 (**Exhibit 10**);
11. Fire A. (1999) RNA-triggered gene silencing. *TIG* 15(9): 358-363 (**Exhibit 11**);
12. Caplen NJ, Fleenor J, Fire A, and Morgan RA. (2000) dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. *Gene* 252: 95-105 (**Exhibit 12**);
13. Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, and Mello CC. (1998) Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. *Nature* 391: 806-811 (**Exhibit 13**);
14. Lue L-F, Walker DG, and Rogers J. (2001) Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. *Neurobiol. Aging* 22: 945-956 (**Exhibit 14**);
15. Carmeliet P, Moons L, and Collen D. (1998) Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. *Cardiovasc. Res.* 39: 8-33 (**Exhibit 15**); and
16. Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) on April 7, 2005 in connection with International Application No. PCT/US2004/036173 (**Exhibit 16**).

Applicants: Shi Du Yan, et al.
U.S. Serial No.: Not Yet Known
Filed: Herewith
Page 4


10/577382

AP20R333PGTPTO 27 APR 2006

Copies of documents numbers 1-16 are attached hereto as **Exhibits 1-16**, respectively.

No fee is deemed necessary in connection with the filing of this Information Disclosure Statement. However, if any fee is required, authorization is hereby given to charge the amount of such fee to Deposit Account No. 03-3125.

Respectfully submitted,



John P. White
Registration No. 28,678
Attorney for Applicants
Cooper & Dunham LLP
1185 Avenue of the Americas
New York, New York 10036
(212) 278-0400

1AP20Resd.PCT/PTO 27 APR 2006

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

3

Complete if Known

Application Number

NOT YET KNOWN

Filing Date

Herewith
20/577382

First Named Inventor

Shi Du Yan

Art Unit

Examiner Name

Attorney Docket Number

68548-PCT-US/JPW/JW

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	International Search Report issued by the International Searching Authority (ISAUS) on April 7, 2005 in connection with International Application No. PCT/US2004/036173	
	2	Tsuji H, Ichihara N, Masugi T, Imura M, Ohkawa J, Arai H, Ishii K, Kita T, and Doi T. (1998) Ribozyme Targeting of Receptor for Advanced Glycation End Products in Mouse Mesangial Cells. Biochem. Biophys. Res. Commun. 245: 583-588	
	3	Bierhaus A, Illmer T, Kasper M, Luther T, Quehenberger P, Tritschler H, Wahi P, Ziegler R, Müller M, and Nawroth PP. (1997) Advanced Glycation End Product (AGE)-Mediated Induction of Tissue Factor in Cultured Endothelial Cells Is Dependent on RAGE. Circulation 96: 2262-2271	
	4	Sajithlal G, Huttunen H, Rauvala H, and Münch G. (2002) Receptor for Advanced Glycation End Products Plays a More Important Role in Cellular Survival than in Neurite Outgrowth during Retinoic Acid-induced Differentiation of Neuroblastoma Cells. J. Biol. Chem. 277(9): 6888-6897	
	5	Yan SD, Chen X, Fu J, Chen M, Zhu H, Roher A, Slattery T, Zhao L, Nagashima M, Morser J, Migheli A, Nawroth P, Stern D, and Schmidt AM. (1996) RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691	
	8	Jen K-Y and Gewirtz AM. (2000) Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Option and Current Strategies. Stem Cells 18: 307-319	
	9	Branch AD. (1998) A good antisense molecule is hard to find. TIBS 23: 45-50	
	10	Green DW, Roh H, Pippin J, and Drebin JA. (2000) Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease. J. Am. Coll. Surg. 191(1): 93-105	
	11	Fire A. (1999) RNA-triggered gene silencing. TIG 15(9): 358-363	
	12	Caplen NJ, Fleenor J, Fire A, and Morgan RA. (2000) dsRNA-mediated gene silencing in cultured Drosophila cells: a tissue culture model for the analysis of RNA interference. Gene 252: 95-105	

Examiner
Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicants: Shi Du Yan, et al.
U.S. Serial No. NOT YET KNOWN
Filed: Herewith (as §371 national stage
of PCT/US2004/036173)
Exhibit A

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	NOT YET KNOWN 68548-PCT-US/JPW/JW
		Filing Date	Herewith
		First Named Inventor	Shi Du Yan
		Art Unit	
		Examiner Name	
Sheet 2 of 3	Attorney Docket Number	68548-PCT-US/JPW/JW	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	13	Fire A, Xu S, Montgomery MK, Kostas SA, Driver SE, and Mello CC. (1998) Potent and specific genetic interference by double-stranded RNA in <i>Caenorhabditis elegans</i> . <i>Nature</i> 391: 806-811	
	14	Lue L-F, Walker DG, and Rogers J. (2001) Modeling microglial activation in Alzheimer's disease with human postmortem microglial cultures. <i>Neurobiol. Aging</i> 22: 945-956	
	15	Carmeliet P, Moons L, and Collen D. (1998) Mouse models of angiogenesis, arterial stenosis, atherosclerosis and hemostasis. <i>Cardiovasc. Res.</i> 39: 8-33	
	16	Written Opinion of the International Searching Authority issued by the International Searching Authority (ISA/US) on April 7, 2005 in connection with International Application No. PCT/US2004/036173	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number **NOT YET KNOWN**

Filing Date	Herewith
-------------	----------

First Named Inventor	Shi Du Yan
----------------------	------------

Art Unit

Examiner Name

Attorney Docket Number	68548-PCT-US/JPW/JW
------------------------	---------------------

Sheet 3 of 3

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.